These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 34531065)

  • 21. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
    Socal MP; Bai G; Anderson GF
    JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anticipatory effects of Medicare Part D on drug utilization.
    Alpert A
    J Health Econ; 2016 Sep; 49():28-45. PubMed ID: 27372577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omnicare forgot to mention ... Part D's effect not factored in its argument for hostile PharMerica takeover.
    Lee J
    Mod Healthc; 2012 Feb; 42(6):14. PubMed ID: 22356083
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicare Part D payments for neurologist-prescribed drugs.
    De Lott LB; Burke JF; Kerber KA; Skolarus LE; Callaghan BC
    Neurology; 2016 Apr; 86(16):1491-8. PubMed ID: 27009256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sending The Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less Than Generics?
    Dusetzina SB; Jazowski S; Cole A; Nguyen J
    Health Aff (Millwood); 2019 Jul; 38(7):1188-1194. PubMed ID: 31260351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medicare part D and long-term care: a systematic review of quantitative and qualitative evidence.
    Pimentel CB; Lapane KL; Briesacher BA
    Drugs Aging; 2013 Sep; 30(9):701-20. PubMed ID: 23729166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
    Sheingold S; Nguyen NX
    Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipitor goes generic: business as usual or more big business?
    Gill L; Santa J; Peter DL; Keehn J
    Ann Intern Med; 2012 Jun; 156(12):892-3, W313. PubMed ID: 22711082
    [No Abstract]   [Full Text] [Related]  

  • 31. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceuticals and Medical Devices: Medicare Part D.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252885
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-28. PubMed ID: 21374839
    [No Abstract]   [Full Text] [Related]  

  • 34. Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017.
    Liu P; Dhruva SS; Shah ND; Ross JS
    Am J Manag Care; 2020 Mar; 26(3):112-117. PubMed ID: 32181626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
    Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
    Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
    Song H; Adamson A; Mostaghimi A
    JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. $4 generics: How low, how broad, and why patient engagement is priceless.
    Rucker NL
    J Am Pharm Assoc (2003); 2010; 50(6):761-3. PubMed ID: 21071325
    [No Abstract]   [Full Text] [Related]  

  • 39. Medicare part D's exclusion of benzodiazepines and fracture risk in nursing homes.
    Briesacher BA; Soumerai SB; Field TS; Fouayzi H; Gurwitz JH
    Arch Intern Med; 2010 Apr; 170(8):693-8. PubMed ID: 20421554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generic-only drug coverage in the Medicare Part D gap and effect on medication cost-cutting behaviors for patients with diabetes mellitus: the translating research into action for diabetes study.
    Duru OK; Mangione CM; Hsu J; Steers WN; Quiter E; Turk N; Ettner SL; Schmittdiel JA; Tseng CW
    J Am Geriatr Soc; 2010 May; 58(5):822-8. PubMed ID: 20406312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.